|Professor Han Bao Hui and professor, Liu Shun from Shanghai Chest Hospital e reported lung cancer research progress in the conference speech in Europe|
In Swiss local time,from April 13 to 16, , the 6th European lung cancer congress (ELCC) was held in Geneva. Professor Han Bao Hui, associate dean of shanghai chest hospital affiliated to shanghai jiao tong university school of medicine, director of oncology, Liu Shun attended the meeting, and reported the latest progress in research on lung cancers for both of them.
European lung cancer conference is one of the world‘s cutting-edge multidisciplinary tumor academic activities, and also one of the events in the medical profession in Europe. The conference attracted global experts and scholars in the field of preclinical research and related professional from oncology, radiation oncology, surgical oncology, and the personage inside course of study in Paris, shared a lung cancer diagnosis and treatment experience, as well as exploring the lung cancer from foundation to the prevention to clinical diagnosis and treatment of the latest progress and ideas. The conference theme invites reports from a number of experts from China and oral research report. professor han bao hui,associate dean of shanghai chest hospital affiliated to shanghai jiao tong university school of medicine, and professor Liu Shun director of oncology brought two important research results about lung cancer in the oral report, which attracted the attention of the international peers and a heated discussion.
On the afternoon of 14th in local time, professor han bao hui introudced EGFR mutations in non-small cell lung cancer treatment special new strategy, and delivered a speech with the title of “in the late sensitive EGFR mutations in patients with lung adenocarcinoma the treatment using joint application in the first-line treatment and chemotherapy (Combination of chemotherapy and gefitinib as first - line treatment of patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomised controlled trial)” research report. Professor han bao hui also pointed out that, EGFR gene mutation of patients with advanced lung adenocarcinoma combination of pemetrexed plus carboplatin the treatment and can get longer progression-free surial. The results for the treatment of patients with EGFR mutations future provides a new train of thought, the use of chemotherapy with targeted drugs as first-line therapy may make patients get longer survival benefit.
On the day before, director of the department of oncology, professor Liu Shun talked around “one American driver mutations metastatic non-small-cell lung cancer: clinical practice Guidelines and (Oligometastatic NSCLC with driver mutations: Guidelines and practical application,” keynote address. In patients with non-small cell lung cancer (NSCLC), the occurrence of metastasis to the limited number of parts and called oligonucleotides transfer, and the prognosis of these patients broader shift is good. Professor Liu Shun pointed out that in the report, oligonucleotides with drive gene transfer of patients with NSCLC patients need considering transfer of organs. The number of transfer and transfer parts and combining the genetic status make treatment decisions, at the same time they combined the necessary local treatment which can bring better survival benefit to patients.